Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Rhythm Pharmaceuticals ( (RYTM) ) just unveiled an update.
On December 11, 2025, Rhythm Pharmaceuticals announced positive preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS). The trial, which enrolled 18 patients, showed potential therapeutic benefits with reductions in BMI and hyperphagia at Months 3 and 6. Encouraged by these results, Rhythm plans to advance setmelanotide into a Phase 3 trial and has initiated a Phase 1 study of another MC4R agonist, RM-718, in PWS patients. The announcement underscores the company’s commitment to addressing the unmet needs of the PWS patient population, which faces significant health challenges due to severe obesity and hyperphagia.
The most recent analyst rating on (RYTM) stock is a Buy with a $136.00 price target. To see the full list of analyst forecasts on Rhythm Pharmaceuticals stock, see the RYTM Stock Forecast page.
Spark’s Take on RYTM Stock
According to Spark, TipRanks’ AI Analyst, RYTM is a Neutral.
Rhythm Pharmaceuticals’ overall stock score is driven by its strong revenue growth and positive technical indicators, suggesting potential for future gains. However, the company’s ongoing profitability challenges and negative valuation metrics weigh heavily on the score. The optimistic sentiment from the earnings call provides some support, but the financial performance remains a significant concern.
To see Spark’s full report on RYTM stock, click here.
More about Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on transforming the lives of patients with rare neuroendocrine diseases. Its lead product, IMCIVREE® (setmelanotide), is an MC4R agonist approved for treating hyperphagia and severe obesity in patients with certain genetic conditions. The company is headquartered in Boston, MA.
Average Trading Volume: 655,798
Technical Sentiment Signal: Buy
Current Market Cap: $6.72B
For a thorough assessment of RYTM stock, go to TipRanks’ Stock Analysis page.